Q1 2024 EPS Estimates for Kymera Therapeutics, Inc. Lifted by Analyst (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at Brookline Capital Management boosted their Q1 2024 earnings estimates for Kymera Therapeutics in a research note issued on Monday, April 8th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.57) for the quarter, up from their prior estimate of ($0.67). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.16) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics’ Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at ($0.17) EPS and FY2024 earnings at ($1.89) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.19. The business had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The company’s quarterly revenue was up 197.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.60) earnings per share.

A number of other brokerages have also issued reports on KYMR. Wells Fargo & Company lowered shares of Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 target price on the stock. in a research report on Tuesday, December 19th. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Piper Sandler raised their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. raised their target price on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Truist Financial raised their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.89.

Kymera Therapeutics Price Performance

KYMR stock opened at $37.21 on Thursday. Kymera Therapeutics has a 12 month low of $9.60 and a 12 month high of $45.31. The company’s 50 day simple moving average is $39.15 and its 200-day simple moving average is $27.04. The firm has a market capitalization of $2.27 billion, a PE ratio of -14.77 and a beta of 2.27.

Insider Activity

In other news, Director Jeffrey W. Albers sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $30.05, for a total value of $300,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the sale, the director now owns 806,697 shares of the company’s stock, valued at approximately $32,638,960.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Albers sold 10,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total transaction of $300,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 484,051 shares of company stock valued at $19,924,711. Company insiders own 16.67% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA grew its holdings in Kymera Therapeutics by 23.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 463,533 shares of the company’s stock worth $6,443,000 after acquiring an additional 86,585 shares in the last quarter. Dark Forest Capital Management LP boosted its holdings in shares of Kymera Therapeutics by 89.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 36,698 shares of the company’s stock valued at $510,000 after buying an additional 17,280 shares during the period. FMR LLC boosted its holdings in shares of Kymera Therapeutics by 3.9% in the 3rd quarter. FMR LLC now owns 870,547 shares of the company’s stock valued at $12,101,000 after buying an additional 32,335 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Kymera Therapeutics in the 3rd quarter valued at about $185,000. Finally, Algert Global LLC boosted its holdings in shares of Kymera Therapeutics by 130.6% in the 3rd quarter. Algert Global LLC now owns 128,532 shares of the company’s stock valued at $1,787,000 after buying an additional 72,802 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.